- Research note
- Open Access
CRISPR/Cas9 genome editing system confirms centriolin’s role in cytokinesis
BMC Research Notes volume 15, Article number: 8 (2022)
In addition to its function as the microtubule organizing center of the cell, the centrosome has functions in many other cellular processes including primary cilia formation, DNA damage checkpoints, and cell cycle progression. But the role of individual components of the centrosome in these processes remains unclear. Previous studies used siRNA (small interfering RNA) to “knock down” protein levels of the centrosome component centriolin, resulting in failed cytokinesis. Since this approach was transient, only targeting centriolin at the mRNA level, we sought to confirm these findings by permanently disrupting the gene encoding centriolin using the CRISPR/Cas9 system of genome editing.
This study provides evidence that the CRISPR/Cas9 system is capable of effectively reducing centriolin protein levels in the cell. Furthermore, this disruption leads to a failure of cytokinesis that is reminiscent of the phenotype previously reported for the siRNA-mediated disruption of centriolin. Furthermore, no additional defects in cell division were observed, consistent with results seen with previous siRNA studies. We conclude that the CRISPR/Cas9 system is an effective means of permanently removing the cellular pools of centriolin and that the disruption of centriolin at both the mRNA level and genomic level lead to similar cell division defects.
The centrosome is the primary microtubule-organizing center in animal cells, located adjacent to the nucleus during interphase. In mitosis, centrosomes form the poles of the mitotic spindle, which is necessary for proper segregation of duplicated centrosomes and the subsequent formation of two normal, diploid daughter cells. Although the centrosome’s role in the organization of the microtubule network inside the cell has been well established , there is significant evidence that components of this organelle may have important functions in many other cellular processes including primary cilia formation , DNA damage checkpoints , cell cycle progression [3,4,5], mitotic exit [1, 3, 6], and cytokinesis [6, 7].
Previously it was shown that one of the components of the centrosome, centriolin, has multiple roles in cell division. It was first observed that this protein is necessary for mitotic exit, as disruption results in aberrant cell division and arrest of the cell in the subsequent G1 phase . Later studies determined that centriolin plays a key role in the final abscission event at the end of cytokinesis, acting as a scaffold at the midbody for the recruitment of complexes that control the membrane fusion events necessary for physical separation of the daughter cells .
These previous studies utilized siRNA targeting the centriolin mRNA in order to eliminate the protein, but effects of disrupting the gene itself were not investigated. In order to determine if the disruption of the centriolin gene would lead to additional cell division defects, we elected to use the genome editing technology CRISPR/Cas9 to permanently eliminate centriolin and then to assay for any abnormal cell cycle phenotypes that result.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 is a RNA-mediated adaptive immune system identified in both bacteria and archaea that has been modified to allow for specific genome editing in eukaryotes . The CRISPR component of this system includes a guide RNA (gRNA), and the Cas9 is a non-specific CRISPR-associated endonuclease. The gRNA is a short RNA molecule whose sequence is complimentary to a specific target DNA sequence in the genome. In the cell, this gRNA is responsible for bringing the Cas9 endonuclease to a specific genomic region based on its sequence, resulting in a double stranded cut in the DNA and effectively disrupting the expression of the targeted gene. To date, this technology has been used to manipulate the genomes of a wide variety of organisms .
In this paper, we describe the abrogation of centriolin function using CRISPR/Cas9. We show that CRISPR/Cas9 can effectively disrupt the production of centriolin protein in Hela cells, and we use immunofluorescence microscopy to show that the centrosomes in these cells are devoid of centriolin. Furthermore, we present evidence that the CRISPR/Cas9-mediated elimination of centriolin causes a cytokinesis defect that is identical to the cytokinesis defect that has been reported previously using siRNA . We conclude that the CRISPR/Cas9 system is an effective means of permanently removing the cellular pools of centriolin and that the disruption of centriolin at both the mRNA level and genomic level lead to similar cell division defects.
Materials and methods
Genomic sequence analysis, guide RNA design, and plasmids
Genomic sequence analysis of the CNTRL locus was obtained from the UCSC Genome Browser (https://genome.ucsc.edu/cgi-bin/hgGateway). The sequence for the centriolin guide RNA (gRNA) was determined using the MIT CRISPR Design tool (http://crispr.mit.edu/). In order to express the gRNA in the cell, the following single stranded DNA oligos were annealed and cloned into the CRISPR/Cas9 expression vector using Gibson Assembly (New England Biolabs, cat# E2611):
5′-TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCCAATATGAGATCT AGGTCACTT -3′ and
5′-GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACAAGTGACCTAGATCTC ATATTGG C
The CRISPR/Cas9 dual-expression vector pSpCas9(BB)-2A-Puro (PX459) was a gift from Feng Zhang (Addgene plasmid # 48139) .
Cell culture and transfections
Hela cells (ATCC-CCL2) were obtained from ATCC and maintained in Eagle’s Minimum Essential Medium (Catalog No. 30-2003) supplemented with 10% fetal bovine serum following the recommended protocol.
Plasmids were transfected into Hela cells using Turbofect reagent (Thermo Scientific) following the manufacturer’s protocol. Following transfection, the cells were selected for puromycin resistance using 0.5 µg/ml puromycin (Fisher BioReagents).
Antibodies, immunofluorescence, and western blotting
Antibodies to the following proteins were used: centriolin (Santa Cruz Biotechnology, cat. # sc-135020), g-tubulin (Invitrogen, cat # MA531482), and α-tubulin (Invitrogen, cat. # 62204). TUNEL assay (Promega, cat # G7360) was performed according to manufacturer’s protocol. For immunofluorescence, cells were fixed in methanol and processed for immunofluorescence as described . All immunofluorescence images were captured on a Nikon Eclipse 50i immunofluorescence microscope equipped with a Nikon DXM1200C digital camera and a 40 × Plan Fluor objective with a 0.75 numerical aperture. Western blotting was performed using standard procedures.
CRISPR/Cas9 targeting of the centriolin gene
In humans, the gene for centriolin (CNTRL) is found on the long arm of chromosome 9 at position 9q33.2 (Fig. 1A). The gene consists of 43 introns and 44 exons, spanning approximately 100 kb. Within exon 3 lies the translational start site for this gene.
In order to disrupt the CNTRL gene and prevent the synthesis of functional centriolin within the cell, a guide RNA (gRNA) was designed that targets the third exon (Fig. 1B). The gRNA binds specifically to a sequence that lies 83 nucleotides downstream of centriolin’s translational start site and is immediately upstream from the obligatory Protospacer Adjacent Motif (PAM) sequence . This sequence is highly conserved among vertebrates, being present in nearly all mammalian species for which genomic data is available (data not shown).
The centriolin gRNA sequence was cloned into the dual-expression vector pSpCas9(BB)-2A-Puro, a plasmid containing both a cloning site for the guide RNA as well as an expression cassette in which the S. pyogenes Cas9 gene is under control of a CBh (CBA (Chicken Beta-Actin) hybrid) promoter. The CBh promoter is an altered version of the CAG (Promoter consisting of cytomegalovirus (CMV) early enhancer element, the promoter region, the first exon, and the first intron of chicken beta-Actin gene, and the splice acceptor of the rabbit beta-Globin gene) promoter  that has been shown to provide robust expression in Hela cells. When expressed in the cell, the S. pyogenes Cas9 creates a double strand break at a specific site within the genome determined by the gRNA, resulting in disruption of the targeted gene. This plasmid also contains a puromycin resistance gene, which was subsequently used to select for transfected cells in the presence of puromycin.
CRISPR/Cas9-mediated reduction in centriolin protein levels
The pSpCas9(BB)-2A-Puro plasmid containing the centriolin gRNA was transfected into exponentially growing Hela cells. After 48 h, the cells were harvested, and cell lysates were generated. A western blot was performed with the cell lysates using antibodies against centriolin or alpha tubulin (loading control). It was found that in the presence of the centriolin gRNA there was a nearly complete elimination of centriolin protein (Fig. 2A, Additional file 3: Fig. S3). The residual centriolin seen is likely due to the fact that the vector that was used was later found to have a mutation in the puromycin resistance gene (https://www.addgene.org/48139/ see “Depositor Comments” section), reducing the selection efficiency.
The transfected cells were also processed for immunofluorescence with antibodies against centriolin and microtubules. As shown in Fig. 2B, treatment with the centriolin gRNA showed no apparent effect on the microtubule array in the cells. This was true of both interphase and mitotic cells. However, there was a near complete absence of centriolin signal at the centrosomes, proving that the gene disruption achieved was sufficient to eliminate the centrosome-associated pool of centriolin.
Loss of centriolin leads to defects in cytokinesis
The treated Hela cells were analyzed for the presence of any morphological changes. Despite the lack of any disruption in the microtubule organization within the cells, it was noted that there was a marked increase in the percentage of multinucleate cells with the centriolin gRNA treatment, which was not observed in the empty vector controls (Fig. 3A and B). The level of multi-nucleation in these cells is consistent with previous studies that used siRNA to disrupt centriolin . This increase in multinucleated cells did not appear to be due to a difference in the rate of cell death as both the empty vector and the centriolin gRNA populations had similar numbers of total cells (Fig. 3A). In addition, the individual nuclei of the cells in both conditions were of similar size (Fig. 3A), suggesting that the effect on the cells is solely a consequence of a failed late stage of division, rather than a defect in DNA replication or in an earlier mitotic stage. Similar results were seen at 96 h, with a slight increase in the number of multinucleated cells (data not shown). Lack of a dramatic increase at this timepoint is likely due to the inhibition of cell cycle progression upon centriolin disruption that was reported previously . Indeed, cell cycle status indicated by centrosome number revealed a robust arrest in G1 for these cells (Additional file 1: Fig. S1). In addition to the multinucleated cells, a perceptible number of cell pairs connected by persistent intercellular bridges was also seen in the centriolin gRNA samples (Fig. 3C), indicating that the cells were unable to complete the final abscission event in cytokinesis. These results did not appear to be due to any effects associated with DNA damage, as our treated cells were negative for TUNEL staining (Additional file 2: Fig. S2). Notably, our data are consistent with the previously reported phenotypes observed when centriolin protein levels were reduced using siRNA .
In this paper, we show that the CRISPR/Cas9 is effective at disrupting the centriolin gene, CNTRL. Treatment of cells with Cas9 along with a guide RNA targeting the third exon of CNTRL results in a significant reduction in centriolin protein. This loss of centriolin leads to a cytokinesis defect reminiscent of the phenotype previously reported when centriolin levels were reduced with siRNA.
The fact that we did not see a complete loss of centriolin and, hence, a greater penetrance of the cytokinesis defect phenotype, is likely due to an inefficient selection of transfected cells in our experiments. A mutation in the puromycin resistance gene in the pSpCas9(BB)-2A-Puro (PX459) has been reported that reduces the effectiveness of the puromycin resistance gene. This required us to use puromycin during our selections at a much lower concentration than is typically used for Hela cells [13,14,15]. Therefore, the inefficient elimination of non-transfected cells brought about by these low concentrations of puromycin is most likely responsible for the residual centriolin detected in our western blots. Nevertheless, the phenotype we report here is consistent with previously published studies in which centriolin protein levels were reduced using siRNA. This confirms that the disruption of the CNTRL gene by CRISPR/Cas9 affects the cell in the same way as the reduction of centriolin protein by siRNA and indicates that the phenotype we have observed is not due to an off-target effect of the CRISPR/Cas9.
A surprising finding that emerged from previous studies was that centriolin did not have any apparent contribution to the centrosome’s function as a microtubule organizing center . When cells were depleted of centriolin with siRNA, the cells retained an intact microtubule network, which appeared to function normally in both interphase and mitosis. Since centriolin localizes to structures inside the centrosome that are known to be anchoring sites for microtubule minus ends , it was expected that elimination of centriolin would adversely affect the cell’s microtubule network. Indeed, we also did not observe any defects in the microtubule network of the cells in our studies. In both our studies as well as those previously published, a complete elimination of the centriolin protein was not achieved. Perhaps a small, residual amount of centriolin is sufficient for its function in organizing microtubules. Future studies are needed to address this possibility.
We have shown that the CRISPR/Cas9 system can be an effective tool for eliminating centriolin, allowing for a more detailed interrogation of its function within the cell. It is worth noting that the sequence that is targeted by our centriolin guide RNA (gRNA) is evolutionarily conserved, being absolutely identical to centriolin homologues in nearly all mammalian species whose genomes have been sequenced to date. Therefore, this gRNA may prove useful in the future to identify centriolin’s cellular function in a multitude of diverse species.
A limitation of our studies is that they were conducted only in Hela cell cultures. It would be important to repeat these experiments in other transformed cell lines, as well as primary cell cultures, to confirm the effects are consistent in other cell types.
Availability of data and materials
The human Centriolin gene (CNTRL) sequence used in this study is NCBI GenBank Accession # NM_007018 XM_005251679 XM_352972 https://www.ncbi.nlm.nih.gov/nuccore/NM_007018.6. Analysis of the CNTRL locus using the UCSC Genome Browser can be found using the following link https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg38&lastVirtModeType=default&lastVirtModeExtraState=&virtModeType=default&virtMode=0&nonVirtPosition=&position=chr9%3A121074955%2D121177610&hgsid=1237244373_hKLofDAhzAxaDJ6ujBvnGnuADlMg. The CRISPR centriolin guide RNA (gRNA) was determined using the MIT CRISPR Design tool http://crispr.mit.edu/. The CRISPR/Cas9 dual-expression vector pSpCas9(BB)-2A-Puro (PX459) was obtained from Addgene https://www.addgene.org/48139/.
Clustered regularly interspaced short palindromic repeats
Small interfering RNA
Protospacer adjacent motif
Doxsey S. Re-evaluating centrosome function. Nat Rev Mol Cell Biol. 2001;2:688–98. https://doi.org/10.1038/35089575.
Jurczyk A, Gromley A, Redick S, SanAgustin J, Witman G, Pazour GJ, Peters DJM, Doxsey S. Pericentrin forms a complex with intraflagellar transport proteins and polycystin-2 and is required for primary cilia assembly. J Cell Biol. 2004;166:637–43.
Gromley A, Jurczyk A, Sillibourne J, Halilovic E, Mogensen M, Groisman I, Blomberg M, Doxsey S. A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase. J Cell Biol. 2003;161:535–45.
Hinchcliffe EH. Requirement of a centrosomal activity for cell cycle progression through G1 into S phase. Science. 2001;291:1547–50. https://doi.org/10.1126/science.1056866.
Khodjakov A, Rieder CL. Centrosomes enhance the fidelity of cytokinesis in vertebrates and are required for cell cycle progression. J Cell Biol. 2001;153:237–42. https://doi.org/10.1083/jcb.153.1.237.
Piel M, Nordberg J, Euteneuer U, Bornens M. Centrosome-dependent exit of cytokinesis in animal cells. Science. 2001;291:1550–3. https://doi.org/10.1126/science.1057330.
Gromley A, Yeaman C, Rosa J, Redick S, Chen CT, Mirabelle S, Guha M, Sillibourne J, Doxsey SJ. Centriolin anchoring of exocyst and SNARE complexes at the midbody is required for secretory-vesicle-mediated abscission. Cell. 2005;123:75–87.
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA—guided. Science. 2012;337:816–22. https://doi.org/10.1126/science.1225829.
Wright AV, Nuñez JK, Doudna JA. Biology and applications of CRISPR systems: harnessing nature’s toolbox for genome engineering. Cell. 2016;164:29–44. https://doi.org/10.1016/j.cell.2015.12.035.
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308. https://doi.org/10.1038/nprot.2013.143.
Dictenberg JB, Zimmerman W, Sparks CA, Young A, Vidair C, Zheng Y, Carrington W, Fay FS, Doxsey SJ. Pericentrin and γ-tubulin form a protein complex and are organized into a novel lattice at the centrosome. J Cell Biol. 1998;141:163–74. https://doi.org/10.1083/jcb.141.1.163.
Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J, Ehlers MD, Zylka MJ, McCown TJ, Samulski RJ. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther. 2011;22:1143–53. https://doi.org/10.1089/hum.2010.245.
Grueneberg DA, Li W, Davies JE, Sawyer J, Pearlberg J, Harlow E. Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc Natl Acad Sci USA. 2008;105:16490–5. https://doi.org/10.1073/pnas.0806578105.
Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28:4104–15. https://doi.org/10.1128/MCB.00289-08.
Ukekawa R, Miki K, Fujii M, Hirano H, Ayusawa D. Accumulation of multiple forms of lamin A with down-regulation of FACE-1 suppresses growth in senescent human cells. Genes Cells. 2007;12:397–406. https://doi.org/10.1111/j.1365-2443.2007.01057.x.
We wish to thank the faculty, staff, and students of the DeBusk College of Osteopathic Medicine for scientific discussion, critical reading of the manuscript, and technical assistance.
This work was supported by an intramural Grant from Lincoln Memorial University-DeBusk College of Osteopathic Medicine to AG and ZG, and the Butterfly Fund of the East Tennessee Foundation (20170452) to AG.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Centriolin CRISPR/Cas9 targeted cells arrest in G1. The number of centrosomes in each cell was determined using g-tubulin stain. One centrosome indicates cells in G1, whereas two centrosomes indicate cells in G2. DAPI staining and morphology were used to separate out the mitotic cells within the G2/M group.
. Centriolin CRISPR/Cas9 does not induce DNA damage. TUNEL staining was performed on Centriolin CRISPR/Cas9 treated cells and control cells. The percentage of TUNEL positive cells was determined by immunofluorescent microscopy. DNAse treated cells were used as a positive control for the TUNEL assay.
About this article
Cite this article
Seronick, E., Son, J., Michael, C. et al. CRISPR/Cas9 genome editing system confirms centriolin’s role in cytokinesis. BMC Res Notes 15, 8 (2022). https://doi.org/10.1186/s13104-021-05898-w